» Articles » PMID: 33299568

Epidemiology of Spinal Cord and Column Tumors

Overview
Date 2020 Dec 10
PMID 33299568
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The spine is a frequent location for metastatic disease. As local control of primary tumor pathology continues to improve, survival rates improve and, by extension, the opportunity for metastasis increases. Breast, lung, and prostate cancer are the leading contributors to spinal metastases. Spinal metastases can manifest as bone pain, pathologic fractures, spinal instability, nerve root compression, and, in its most severe form, spinal cord compression. The global extent of disease, the spinal burden, neurologic status, and life expectancy help to categorize patients as to their candidacy for treatment options. Efficient identification and workup of those with spinal metastases will expedite the treatment cascade and improve quality of life.

Citing Articles

Patterns of Treatment Delay in Patients with Symptomatic Metastatic Epidural Spinal Cord Compression.

Wang S, Hallinan J, Tan C, Chua K, Teo A, Kumar N Cancers (Basel). 2025; 17(4).

PMID: 40002190 PMC: 11852822. DOI: 10.3390/cancers17040595.


Does an Unintended Durotomy in Metastatic Spine Surgery Lead to Shorter Survival?.

Gangavarapu L, Chanbour H, Bendfeldt G, Younus I, Jonzzon S, Chotai S Neurosurg Pract. 2025; 5(3):e00096.

PMID: 39959893 PMC: 11783639. DOI: 10.1227/neuprac.0000000000000096.


Enhancer Dynamics and Spatial Organization Drive Anatomically Restricted Cellular States in the Human Spinal Cord.

Kandror E, Wang A, Carriere M, Peterson A, Liao W, Tjarnberg A bioRxiv. 2025; .

PMID: 39829819 PMC: 11741326. DOI: 10.1101/2025.01.10.632483.


Advanced Radiotherapy Technologies in Spine Tumors: What the Surgeon Needs to Know.

Chen H, Ghia A, Maralani P, Bettegowda C, Boriani S, Dea N Global Spine J. 2025; 15(1_suppl):104S-119S.

PMID: 39801121 PMC: 11726527. DOI: 10.1177/21925682241229665.


Liquid Biopsy for Spinal Tumors: On the Frontiers of Clinical Application.

Tan S, Bettegowda C, Yip S, Sahgal A, Rhines L, Reynolds J Global Spine J. 2025; 15(1_suppl):16S-28S.

PMID: 39801114 PMC: 11726521. DOI: 10.1177/21925682231222012.


References
1.
Amer M, Al-Sarraf M, Baker L, VAITKEVICIUS V . Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978; 42(2):660-8. DOI: 10.1002/1097-0142(197808)42:2<660::aid-cncr2820420237>3.0.co;2-e. View

2.
Kelley S, Ashford R, Rao A, Dickson R . Primary bone tumours of the spine: a 42-year survey from the Leeds Regional Bone Tumour Registry. Eur Spine J. 2006; 16(3):405-9. PMC: 2200710. DOI: 10.1007/s00586-006-0188-7. View

3.
Walkington L, Coleman R . Advances in management of bone disease in breast cancer. Bone. 2010; 48(1):80-7. DOI: 10.1016/j.bone.2010.05.037. View

4.
Li S, Peng Y, Weinhandl E, Blaes A, Cetin K, Chia V . Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol. 2012; 4:87-93. PMC: 3345874. DOI: 10.2147/CLEP.S28339. View

5.
Vinholes J, Coleman R, Eastell R . Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev. 1996; 22(4):289-331. DOI: 10.1016/s0305-7372(96)90021-3. View